Eton Pharmaceuticals, Inc. (ETON) Stock Analysis
A live, multi-source view of Eton Pharmaceuticals, Inc. (ETON): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Sector: Healthcare · Industry: Drug Manufacturers - Specialty & Generic · United States · 44 employees · etonpharma.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Eton Pharmaceuticals, Inc. (ETON) had a market capitalization of $1.67B, a trailing P/E of 149.9 (forward 22.7) and a beta of 0.90; the shares traded in a 52-week range of $14.27 – $66.37 (228.7% over the year).
- Market cap
- $1.67B
- Enterprise value
- $1.67B
- Trailing P/E
- 149.9
- Forward P/E
- 22.7
- Price / book
- 35.49
- EPS (trailing)
- $0.39
- EPS (forward)
- $2.58
- Payout ratio
- 0.0%
- 52-week range
- $14.27 – $66.37
- 52-week change
- 228.7%
- Beta
- 0.90
- Average volume
- 549,446
- Shares outstanding
- 28.6M
- Short % of float
- 6.91%
- Profit margin
- 12.0%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-08
In RapidTradeView’s 2026-09-08 scan of the US universe, Eton Pharmaceuticals, Inc. (ETON) last closed at $58.45 (the last completed close before that scan).
Technicals at the scan: RSI 57 (neutral territory), price +1.6% versus its 20-day average, 20-day versus 50-day average spread +20.5%, MACD histogram -0.78.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 75/100.
Next scheduled company event: in 65 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
RapidTradeView has recorded no Congress or insider filing for ETON in the last 90 days. Coverage of House, Senate and SEC Form 4 filings began in July 2026, and insider sells are tracked for universe tickers only, so this is our record, not a guarantee that nothing was filed. Who is trading what
RapidTradeView pick record
ETON has not appeared in the daily picks yet. Full scoreboard
What this page covers
RapidTradeView pulls Eton Pharmaceuticals, Inc. (ETON) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell ETON.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.